Third Generation Cd20 Targeted Car T-Cell Therapy (Mb-106) For Treatment Of Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Background: Chimeric antigen receptor T-cell (CAR-T) therapy is an effective strategy for patients (pts) with B-cell non-Hodgkin lymphomas (B-NHLs). However, long-term remissions are only observed in ~40% of pts with large cell lymphomas (LCL) treated with FDA-approved CD19-targeted products and there is currently no approved CAR-T for other histologies other than mantle cell lymphoma (MCL). CD20 is a proven therapeutic target for B-NHL, supported by previously approved naked and radiolabeled anti-CD20 antibodies and promising results from bispecific antibodies. CD20-targeted CAR-T is another potential adoptive immunotherapy option that could be utilized in combination or in sequence with CD19 CAR-T. We present interim results of our ongoing phase I/II clinical trial investigating safety and efficacy CD20 CAR-T for high-risk B-NHLs (NCT03277729).